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Background: Recent studies have demonstrated a possible association between
myocardial injury after transfemoral (TF) TAVR and (1) adverse clinical events, and
(2) a decreased improvement in left ventricular ejection fraction (LVEF).
Methods: Patients (pts) from the PARTNER trial (randomized and continued
access cohorts) treated with TF-TAVR who had baseline and 24h cardiac marker
values (cardiac troponin I [cTnI] and/or creatine kinase-MB [CKMB]) were
included in the analysis. Pts were divided into tertiles (T1, T2, T3) based on the
difference between the 24h and the baseline values of each cardiac marker (DcTnI
and DCKMB). Clinical and echocardiographic outcomes were compared between
tertiles.
Results: A total of 546 pts were included in the DcTnI analysis (T1 [-3.76 to 0.29
ng/mL])¼180, T2 [0.30 to 0.85 ng/mL]¼184, T3 [0.88 to 57.96 ng/mL])¼182),
while 629 pts comprised the DCKMB analysis (T1 [-80.0 to 0.8 U/L]¼208, T2 [0.9
to 2.9 U/L]¼213, T3 [3.0 to 85.9 U/L]¼208). At 30 days, patients in the highest
tertile (T3) of cardiac biomarker elevation, as compared with patients in the lowest
tertile (T1), had a statistically higher rate of all-cause mortality (DcTnI: T3: 5.5% vs
T1: 0.6%, p¼0.006; DCKMB: T3: 5.8% vs T1: 1.0%, p¼0.007) and cardiovascular
mortality (DcTnI: T3: 5.0% vs T1: 0.6%, p¼0.011; DCKMB: T3: 3.9% vs T1:
0.5%, p¼0.018). The 30-day rates of myocardial infarction were similar across the
tertiles for both markers (DcTnI: p¼0.3240, DCKMB: p¼0.3594). At 1 year, only
the highest CKMB tertile was statistically associated with higher all-cause
mortality (DcTnI: T3: 23.9% vs T1: 19.8%, p¼0.225; DCKMB: T3: 25.9% vs T1:
17.9%, p¼0.029) (ﬁgure1) and higher cardiovascular mortality (DcTnI: T3: 18.8%
vs T1: 12.3%, p¼0.859; DCKMB: T3: 17.1% vs T1: 10.2%, p¼0.029). After
multivariable analysis, the highest tertiles of cardiac biomarker elevations remained
independent predictors of 30-day and 1 year all-cause mortality. The degree of
myocardial injury did not inﬂuence the improvement of NYHA class (DcTnI:
p¼0.1971, DCKMB: p¼0.2149) or LVEF(DcTnI: p¼0.7187, DCKMB: p¼0.8298)
at 1 year.O
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cardiac enzyme elevations were associated with higher 30-day (cTnI and CKMB)
and 1-year all-cause and cardiovascular mortality (CKMB) rates. The degree of
myocardial injury had no impact on improvement of the NYHA class or recovery of
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Background: The PARTNER trial demonstrated superior survival with transcatheter
aortic valve replacement (TAVR) compared to standard therapy (ST) in inoperable
patients with symptomatic, severe aortic stenosis (AS). We sought to evaluate the
effect of left ventricular (LV) dysfunction on clinical outcomes and the impact of
management approach on LV functional recovery.
Methods: The PARTNER trial cohort B randomized inoperable patients with severe
AS to TAVR or ST. Patients were stratiﬁed by the presence of LV ejection fraction
(LVEF) <50%. Improvement in LVEF was deﬁned as an 10% absolute improve-
ment in LVEF at 30-days.
Results: Left ventricular dysfunction was present in 118 patients (59 TAVR and 59
ST patients). Baseline LV dysfunction was associated with an increased risk of
cardiac mortality at 1-year with ST (HR¼1.71 [95% CI 1.08, 2.71]; P¼0.02) but
not with TAVR. TAVR was associated with survival advantage regardless of
baseline LVEF. Improvement in LVEF occurred in 48.7% and 31.0% of TAVR
and ST patients, respectively (P¼0.16). Smaller LV diastolic dimensions and
higher aortic valve gradients were associated with increased likelihood of LVEF
improvement during ST which in turn was associated with markedly reduced all-
cause mortality rates (HR¼0.32 [95% CI 0.11, 0.93]; P¼0.03). Improvement in
LVEF did not impact outcomes after TAVR. All-cause mortality at 1-year was
similar in those with LVEF improvement during ST and after TAVR (28.6 vs
31.6%; P¼0.84).
Conclusions: In inoperable patients with severe AS, TAVR is associated with
improved survival regardless of baseline LVEF and should be considered the standard
of care for inoperable patients with symptomatic severe AS and LV dysfunction.
Improvement in LVEF during ST portends favorable survival that is similar to that
seen after TAVR in inoperable patients.
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Background: Permanent pacemaker implantation (PPI) is frequently required after
transcatheter aortic valve replacement (TAVR), but limited data is available regarding
predictors and clinical consequences.
Methods: Patients without prior PPI who underwent TAVR in the PARTNER
Trial and randomized continued access registry were included in this analysis.
Multivariable analysis was performed to identify clinical, EKG, and echocar-
diographic (Echo) predictors of PPI after TAVR. Clinical and Echo outcomes
were compared between patients with and without PPI within 30 days of
TAVR.acts/ORAL/TAVR - Outcomes B37
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frequent prior chest wall radiation (5.2% vs 2.4%, p¼0.04); baseline EKG ﬁndings
of bradycardia (sinus, sinus pauses, or junctional)(4.1% vs 1.2%, p¼0.01), right
bundle branch block (RBBB)(45.9% vs 12.6%, p<0.001), and left anterior fascic-
ular block (15.9% vs 7.3%, p<0.001); and Echo ﬁndings of smaller left ventricular
(LV) end-diastolic dimension (4.26 cm vs 4.43 cm, p¼0.05) and LV outﬂow tract
(LVOT) diameter (1.97 cm vs 2.01 cm, p¼0.03), and larger ratio of annulus to
LVOT diameter (1.08 vs 1.06, p¼0.006) and prosthesis to LVOT diameter (1.23 vs
1.21, p¼0.001). By multivariable analysis, independent predictors of PPI included
prosthesis/LVOT diameter (OR 11.0, p¼0.003), RBBB (OR 6.2, p<0.001), and
bradycardia (OR 3.6, p¼0.018). At 1 year, PPI was associated with repeat hospi-
talization (24.7% vs 18.6%, p¼0.03), but not with mortality (26.7% vs 21.6%,
p¼0.11), cardiovascular mortality (15.1% vs 13.4%, p¼0.59), stroke (3.5% vs 5.9%,
p¼0.27), or myocardial infarction (2.4% vs 1.8%, p¼0.93). There were no signiﬁ-
cant differences in LV ejection fraction (EF), LV end-systolic dimension, or heart
failure symptoms (NYHA class) at 1 year.
Conclusions: PPI was required in 8.8% of patients without prior PPI undergoing
TAVR with a balloon-expandable valve. Independent predictors of PPI included the
ratio of valve prosthesis diameter to LVOT diameter, baseline RBBB, and brady-
cardia. PPI was not associated with major adverse cardiovascular events or differences
in LV function at 1 year.
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Background: Implantation of a transcatheter valve into a degenerated bioprosthesis
during aortic valve-in-valve procedure (VinV) might signiﬁcantly reduce the
effective oriﬁce area (EOA) available for blood ﬂow. We sought to investigate the
impact of prosthesis-patient mismatch (PPM) on hemodynamics and survival in
these patients.
Methods: Two hundred and twenty data sets of aortic VinV procedures from the
Global Valve-in-Valve Registry were investigated. Severe PPM was deﬁned as an
indexed EOA < 0.65cm2/m2 patient body surface area (BSA).
Results: Severe PPM was present in 70 patients after aortic VinV implantation
(31.8%, age 80  9.4 years, 60% men). The incidence of severe PPM was higher in
patients who received a SAPIEN device vs. a CoreValve (43.8% vs. 15.2%,
p<0.0001). Patients with severe PPM had larger body weight (80.6  16 kg vs. 72.4
 15.1, p¼0.0003), larger BSA (1.94  0.23 m2 vs. 1.82  0.22, p<0.0001), higher
aortic mean gradient after the procedure (20.7  9.2 mmHg vs. 13.8  7.2) and lower
aortic valve area (1.03  0.19 cm2 vs. 1.62  0.44), in comparison with patients
without severe PPM. In patients who survived aortic VinV implantation procedure,
one-year survival was not affected by having severe PPM (86.7% vs. 89.1% in
patients without severe PPM, log rank p¼0.69).
Conclusions: Severe PPM is common after aortic VinV implantation, occurring in
approximately one-third of patients and more frequently after SAPIEN device
implantation. Despite higher valve gradients in patients with severe PPM, one-year
survival was similar to those without severe PPM.B38 JACC Vol 62/18/Suppl B j OctoTCT-117
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Background: In the randomized PARTNER trial of transcatheter aortic valve
replacement (TAVR) for high-risk aortic stenosis, TAVR via the transapical (TA)
approach was associated with worse health-related quality of life (HRQOL) in the
short-term compared with surgical aortic valve replacement (SAVR). Since
PARTNER A represented the ﬁrst TA-TAVR procedures for many study sites, it is
possible that results have improved with greater experience. We therefore examined
HRQOL after TA-TAVR in the non-randomized continued access registry (NRCA) of
the Edwards-Sapien valve and compared these outcomes with patients from the
randomized controlled trial (RCT).
Methods: Patients undergoing TA-TAVR in the NRCA of the Edwards Sapien
valve underwent standardized health status assessments using the Kansas City
Cardiomyopathy Questionnaire (KCCQ), the Short Form-12 (SF-12), and the Euro-
Qol-5D (EQ-5D) at baseline, 1 month (m), 6 m, and 12 m after TAVR. Post-procedure
health status outcomes were compared with those of the TA cohort of the PARTNER
RCT who were treated with either TA-TAVR or SAVR.
Results: Among NRCA TA-TAVR patients with evaluable data, the overall KCCQ
summary score increased by 12.6 points at 1 m (n¼704), 25.8 at 6 m (n¼608), and
25.1 at 12 m (n¼504) (p<0.001 for all compared with baseline). Compared with
RCT-TA patients, there were no signiﬁcant differences in HRQOL at 12 m, but there
were trends toward greater improvements at 1 and 6 m. Compared with RCT-SAVR
patients, there were no signiﬁcant differences in health status outcomes at any
follow-up timepoints (mean difference in KCCQ Overall Summary Score adjusted
for baseline: -1.8 at 1 m, -3.8 at 6 m, 1.8 at 12 m; all p¼NS). Similar results were
seen for the SF-12 physical (0.9 at 1 m; -1.1 at 6 m; 0.2 at 12 m; all P¼NS) and
mental (-1.4 at 1 m; -0.3 at 6 m; -0.9 at 12 m; all P¼NS) component summary
scores.
Conclusions: Improvements in both disease speciﬁc and generic health status among
patients in the NRCA cohort undergoing minimally invasive TA-TAVR with the
Sapien valve were similar to (but not better than) those of SAVR as performed within
the randomized PARTNER trial.
TCT-118
A Multidisciplinary, Multimodality, But Minimalist (3M) Approach To
Transfemoral Transcatheter Aortic Valve Replacement Facilitates Safe
Next Day Discharge In High Risk Patients
David A. Wood1, Rohan S. Poulter2, Richard Cook3, Sandra Lauck4,
Philippe Genereux5, Iefan Lim2, Nigussie Bogale6, Ronald K. Binder7,
Marco Barbanti8, Danny Dvir9, Melanie Freeman10, Mathieu Lempereur11,
Imran Shiekh11, John Tan4, John Jue2, Ken Gin2, P. K. Lee11, Parvathy Nair11,
Teresa S. Tsang11, Jonathon K. Todd11, Anson Cheung10, Jian (James) Ye12,
Jonathon A. Leipsic13, David Cohen14, Martin Leon15, Webb John10
1Centre for Heart Valve Innovation, Vancouver, British Columbia, 2University of
British Columbia, Vancouver, British Columbia, 3University of british Columbia,
Vancouver, British Columbia, 4St. Paul's Hospital, Vancouver, British Columbia,
5Cardiovascular Research Foundation, , New York, NY, NY, 6Vancouver General
Hospital/University of British Columbia, Vancouver, BC, 7University of Zurich,
Zurich, Switzerland, 8St. Paul's Hospital - University of British Columbia, Vancouver,
British Columbia, 9St Paul's Hospital, Vancouver, British Columbia, 10St Pauls
Hospital, Vancouver, British Columbia, 11Vancouver General Hospital, Vancouver,
British Columbia, 12St. Pauls Hospital, Vancouver, British Columbia, 13St. Paul's
Hospital, Vancouver, Canada, 14Saint Luke's Mid America Heart Institute, Kansas
City, United States, 15Cardiovascular Research Foundation, New York, NY
Background: TAVR is an acceptable alternative to surgery in high risk patients;
however, complications and cost currently limit expansion into lower risk pop-
ulations. Although mortality, vascular injury, stroke, paravalvular regurgitation and
length of stay (LOS) are expected to improve, we sought to determine ifber 27–November 1, 2013 j TCT Abstracts/ORAL/TAVR - Outcomes
